Male patients with terminal renal failure exhibit low serum levels of antimüllerian hormone

来源 :亚洲男性学杂志(英文版) | 被引量 : 0次 | 上传用户:ganmaogaishilangren
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Male reproductive function is impaired during end?stage renal disease (ESRD). Disturbance of the hypothalamic?pituitary?gonadal axis, and therefore the regulation of sex hormones, is one of the major causes. Our focus was to include antimüllerian hormone (AMH) and inhibin B concentrations. Twenty male patients on hemodialysis, median age 40 (26–48) years, were analyzed for follicle?stimulating hormone (FSH), luteinizing hormone (LH), prolactin, sex hormone?binding globulin (SHBG), testosterone, estradiol, AMH and inhibin B levels. We used 144 proven fertile men, median age 32 (19–44) years as a control group and analyzed differences using multiple linear regression. Males with ESRD demonstrated higher mean values for prolactin, 742 versus normal 210 mIE l?1 (95% confidence interval (CI): 60.3, 729), LH, 8.87 versus normal 4.5 IE l?1 (95% CI: 2.75, 6.14), and estradiol 89.7 versus normal 79.0 pmol l?1 (95% CI: ?1.31, ?0.15). Mean value for AMH was lower, 19.5 versus normal 47.3 pmol l?1 (95% CI: ?37.6,?11.6). There were no differences found for FSH, SHBG, inhibin B and testosterone. The most important difference was found for AMH, a marker of Sertoli cell function in the testes, which decreased by close to 60% when compared with controls. Combined with an increase in LH, these findings may indicate a dysfunction of Sertoli cells and an effect on Leydig cells contributing to a potential mechanism of reproductive dysfunction in men with ESRD.
其他文献
期刊
Comprehensive identification of driver mutations in prostate cancer can serve to enhance our understanding of the disease and expand the use of available treatment options.Two recent and complementary studies from Barbieri et al.1 and Grasso et al.2 have
期刊
We performed a meta?analysis to compare treatment with a combination of solifenacin plus tamsulosin oral controlled absorption system (TOCAS) with placebo or TOCAS monotherapy. The aim of the meta?analysis was to clarify the efficacy and safety of the com